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INTRODUCTION 
Attending toward and focusing on pain are central components in many psychological models 
of chronic pain [25,26,48,58,62]. In particular, an ‘attentional bias’ toward pain, the tendency to 
select pain-related information over non-pain information, is argued to increase the salience of 
pain, enhance fear and catastrophizing, motivate avoidance of painful activities, and increase 
disability. Given this crucial role, studies have begun to investigate whether pain-related attention 
biases can be modified and whether this modification impacts pain and pain-related outcomes. One 
tool for this purpose is Attention Bias Modification (ABM), a computerized training protocol that is 
proposed to train participants’ attention away from pain-related stimuli, possibly by altering top-
down attention control [5,35]. 
ABM has been shown to increase cold pressor pain thresholds in healthy adults [3,43,54], and 
to significantly reduce pain intensity and frequency in adults with acute back pain [53]. In chronic 
pain samples, one uncontrolled study [52] and one placebo-controlled study [9] provided evidence 
that ABM decreases pain symptoms, although a third placebo-controlled study did not replicate 
these findings [53]. Studies with chronic pain samples have also provided evidence that ABM 
significantly reduces pain-related outcomes such as anxiety sensitivity [43,53], functional disability 
[53], and anxiety and depression symptoms [52]. Taken together, there is preliminary evidence that 
ABM may be efficacious for improving pain and pain-related outcomes, although findings across 
studies are mixed and additional, randomized-controlled trials are needed [59].  
No studies have yet employed ABM for adolescents with chronic pain, despite previous 
findings that selective attention biases characterize paediatric patients with chronic pain  [2,4] and 
that therapeutic techniques targeting attention, particularly attention control can moderate 
adolescents’ cognitive-affective response to pain as well as pain outcomes [33,34]. Strategies such 
as ABM that can encourage improvements in attention control ability – particularly at a 
developmental juncture when there are age-typical changes in mastery over attention [15,44] and 
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associated maturation of brain regions engaged in goal-directed attention control [44,46,57] – may 
be especially beneficial. In addition, as chronic pain often first emerges in adolescence [47], 
investigating the plasticity and impact of pain-related attention during adolescence may allow 
consideration of its role in the early emergence and maintenance of chronic pain.   
Here we report a three-arm randomized, placebo-controlled, parallel-group trial of multi-
session ABM in adolescents with chronic non-cancer pain. We predicted that ABM, relative to 
placebo training and no training (waitlist), would significantly reduce attention bias to pain-related 
stimuli while also increasing attention control. We also expected that ABM would lead to relative 
improvements in pain symptoms and pain-related outcomes, namely pain catastrophizing, anxiety 
and depression symptoms, and functional disability. We examined effects of ABM on pain and 
pain-related outcomes immediately after training and three months later, to examine whether 
training effects maintained or emerged over time.   
 
METHODS 
This study was registered on the NIHR Clinical Research Network Portfolio in August 2014 
(UK Clinical Trials Gateway: CPMS 17251). 
 
Participants 
Adolescents aged 10-18 years with chronic non-cancer pain were recruited from the Oxford 
Centre for Children and Young People in Pain (OxCYPP), part of the Nuffield Orthopaedic Centre 
at the Oxford University Hospitals. OxCYPP is part of an orthopaedic musculoskeletal referral 
system receiving referrals from gastroenterology, neurology, orthopaedics, spinal units, 
rheumatology, and General Practitioners. Patients were eligible for the current study if they 
reported recurrent or persistent pain for more than three months. Participants were excluded if they 
were currently experiencing severe distress based on expert clinician judgment by a consultant 
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clinical psychologist, or did not understand English. Patients were only eligible to take part in the 
study if they were not scheduled to receive multidisciplinary inpatient treatment, or regular 
psychological treatment, during the intervention (training) phase. However, patients were permitted 
to continue attending infrequent (once per week or less) outpatient sessions, including with the 
occupational therapist or physiotherapist, primarily for assessments. Some patients were also 
seeking additional complementary and alternative treatments outside of the hospital setting, 
including acupuncture and nutritional support. These treatments were also permitted if they were 
being received infrequently (once per week or less). We recruited participants between October 
2014 and April 2016, and the final assessment session took place in August 2016. Participants were 
recruited primarily for the current study investigating ABM training, but we also collected 
measures of interpretation bias at baseline (data reported elsewhere; [32]). Patients and a 
parent/guardian were first approached about the study either following their first assessment 
session at the clinic, or following their second visit to the clinic during which they attended a pain 
education class with a small group of other patients and families. During these sessions, a 
paediatric rheumatologist or the consultant clinical psychologist approached patients and their 
families and asked if they would like to learn more about taking part in a research study. A member 
of the research team subsequently provided the families who were happy to be approached with an 
information sheet, answered questions about the study, and scheduled appointments. Seventy-three 
patients were interested in the study, and 67 agreed to take part. Reasons for not participating in the 
study were not recorded for patients who were approached but declined to take part. A CONSORT 
diagram illustrating the flow of participants through each stage of the trial is shown in Figure 1. 
The first patient was recruited as a pilot participant and only completed a small number of 
measures to examine feasibility of testing in the hospital setting, and so the data from this patient 
were excluded from analyses. Thus, 66 patients were enrolled in the full study (55 female; M = 
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13.97 years; SD = 2.13). This study was approved by the UK National Research Ethics Service 
(REC reference 14/SC/0246).  
 
Procedures 
Recruitment and assessment sessions took place at the Nuffield Orthopaedic Centre. At the 
baseline assessment session, parents/guardians first provided informed consent for their children. In 
addition, participants aged 16 or over provided informed consent for themselves. Participants 
younger than 16 years provided informed assent. Randomisation took place following consent. 
 
Randomisation and Allocation Concealment 
Eligible participants were randomly assigned to one of the three treatment arms (ABM, 
placebo, or waitlist), with an equal allocation ratio, based upon a computerized random number 
generator (www.random.org/). The principal investigator (LCH) performed randomisation 
following successful recruitment and consent, thus allocation to treatment arm was fully concealed 
to participants and to the research team prior to assignment.  
 
Blinding 
 Participants assigned to ABM or placebo training were blinded to their treatment condition 
throughout the trial. Given that participants assigned to the waitlist condition were told that they 
would not receive the training tasks until after the final assessment session, it was not possible to 
blind participants assigned to the waitlist condition. Study physicians involved in the participants’ 
otherwise normal care were blind to allocation. Only the principal investigator (LCH), who 
conducted all assessment sessions, was aware of the participants’ treatment conditions out of 
necessity for sending participants the correct training protocol.  
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Training Protocols 
Participants in the ABM and placebo training groups were asked to complete eight training 
sessions, twice per week over four weeks. Participants were encouraged to do the training during 
normal waking hours, and to allow at least one day between the sessions. SMS reminders were sent 
to participants, parents, or both depending on the family’s preference. Participants in the waitlist 
group did not complete any training between the baseline and post-training assessment, but were 
given the opportunity to complete the training after the final (follow-up) assessment session.  
 
Assessment Sessions 
At the baseline assessment session, we collected demographic information and clinical 
history. At all assessment sessions (baseline, post-training, and follow-up) participants completed 
the measure of pain symptoms (primary outcome), followed by the measures of attention bias and 
attention control, physical tests (as an index of functional disability), and finally self-reported 
functional disability, pain catastrophizing, and anxiety and depression symptoms. The post-training 
assessment was completed within seven days of completing the last training session, and the 
follow-up assessment was completed three months after the post-training assessment. In addition to 
the measures described above, participants completed two additional questions at the post-training 
assessment to provide subjective feedback on the training. Participants were compensated with an 
Amazon voucher after each assessment session (vouchers worth £100 in total), and travel expenses 
were reimbursed to parents. All adverse events, regardless of whether they were study-related, were 
monitored throughout and reviewed by the principal investigator (LCH) at each study assessment.  
 
ABM and Placebo Training 
ABM and placebo training were delivered using modified versions of the dot-probe task 
[39] (see Figure 2). During ABM and placebo training, stimuli were presented against a black 
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background. Each trial began with a 500ms presentation of a white fixation cross in the middle of 
the screen. Participants were instructed to fixate their gaze on this location. Then, one stimulus pair 
comprising a pain-related stimulus and a neutral stimulus appeared and remained visible for 500ms 
(for a similar protocol see [53]). One stimulus was presented above and one below the fixation 
cross, with the distance from the stimuli to the centre of the screen as one-fourth the height of the 
screen. Immediately after the offset of these two stimuli, a letter ‘p’ or ‘q’ would appear in place of 
one of the stimuli (the probe). During ABM training, the probe always appeared in the previous 
location of the neutral stimulus, and stimulus pairs were randomly presented in each of the two 
possible combinations (probe up/pain stimulus down; probe down/pain stimulus up). Hence, the 
aim of the ABM training was developed to train participants to attend away from pain-related 
stimuli. During placebo training, the probe appeared equally often in the location of the pain-
related stimulus and the neutral stimulus, and thus stimulus pairs were randomly presented in each 
of the four possible combinations (probe up/pain stimulus up; probe up/pain stimulus down; probe 
down/pain stimulus down; probe down/ pain stimulus up). In both training conditions, participants 
had to indicate whether the probe was a ‘p’ or a ‘q’ by pressing the corresponding button on the 
(QWERTY) keyboard as quickly as possible. The ‘q’ key was pressed with the left index finger and 
the ‘p’ key was pressed with the right index finger. A new trial started after each response, or 
automatically when 2500ms elapsed without response. When a participant responded erroneously, 
the term ‘error’ briefly appeared on the screen (200ms). In order to ensure that participants 
maintained gaze at the middle of the screen, a number of digit trials were presented (see e.g., 
[34,51]). In these trials, the fixation cross was followed by a random digit between 1 and 9 for a 
duration of 150ms. Participants were instructed to type the number on the keyboard. The inter-trial 
interval was 1000ms. In the context of the current study, congruent trials were those where the 
probe was presented at the same location as the pain stimulus. Incongruent trials were those where 
the probe was presented at the same location as the neutral stimulus. Each training session 
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consisted of 210 training trials (96 congruent trials, 96 incongruent trials, 18 digit trials), taking 12 
minutes for participants to complete. Stimuli were presented in a randomized order across trials and 
participants, and trials were intermixed and randomly presented in two blocks, with a break 
between block one and block two.  
The dot-probe tasks were programmed and presented using the INQUISIT Millisecond 
software package (INQUISIT 4.0). INQUISIT measures response times (RTs) with millisecond 
accuracy (Inquisit 4.0; Millisecond Software, Seattle, WA, USA). Participants completed all ABM 
and placebo training at home, using the INQUISIT Web interface. This interface allows 
participants to access each training task using a unique webpage address. The INQUISIT 
programme is downloaded to the participant’s local computer using a plugin. Each time the 
participant finished the task, a data-file with the participant’s accuracy and response time scores is 
securely saved to the experimenter’s INQUISIT account, allowing the experimenter to verify that 
the participant had completed each training task, and to monitor the participant’s performance.  
 
Measures 
All primary and secondary outcome measures, and measures of attention bias and attention 
control, were completed at baseline, post-training assessment, and follow-up assessment. Details of 
training tasks and assessment measures are given below.  
 
Demographics 
At baseline, participants reported on demographic information including gender, age, 
ethnicity, school status, and number of siblings. Participants also reported on the onset of their pain 
(sudden or gradual), time since pain onset (months), and body locations where they experience 
pain.  
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Primary Outcome: Pain Symptoms 
To assess pain symptoms, participants completed two 11-point visual analogue scales 
indicating their average pain intensity in the last week, and their pain intensity at the body part they 
experienced most problems within the last week (hereafter referred to as ‘most problematic pain’) 
(0 = no pain; 10 = worst pain possible), as well as one 4-point visual analogue scale indicating the 
average duration of their pain each day in the last week (1 = less than one hour; 4 = all day). All 
items were derived from the Brief Pain Inventory [14].  
 
Secondary Outcomes 
Physical Disability  
Participants’ physical disability was assessed with one self-report measure and two physical 
tasks. The self-report measure (FDI) was the primary measure of physical functioning.  
First, participants completed the Functional Disability Inventory (FDI) that assesses 
perceived difficulty in performing common activities in the domains of school, home, recreation, 
and social interactions. Participants rate the difficulty they had in carrying out each activity in the 
preceding two weeks (0 = no trouble; 4 = impossible). The FDI consists of 15 items and yields a 
total score that can range from 0 to 60, with higher scores indicating greater disability. The FDI has 
yielded good reliability and validity for children and adolescents [63] and for youth with chronic 
pain [37]. Cronbach’s alpha for our sample was .90 at baseline.  
Second, two objective assessments of physical function were conducted. Participants 
completed the Sit-to-Stand task, which comprised participants attempting to move from a seated to 
a standing position as many times as possible within 30 seconds. Participants also completed the 
Cardio Wall task (http://embeddedfitness.nl/en/exergames/cardio-wall-2/), an interactive task in 
which participants are required to tap (using their hands) lights on a wall for 30 seconds. 
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Participants must reach high and bend down low to tap the lights, and the maximum height can be 
adjusted according to the height of the participant.  
 
Pain Catastrophizing 
We assessed participant’s catastrophic thoughts about pain using the Pain Catastrophizing 
Scale for Children (PCS-C) [18]. Pain catastrophizing is comprised of rumination, magnification, 
and helplessness. Participants rated 13 items on a 0-4 scale to create a total score from 0 to 52. 
Higher scores indicate more pain catastrophizing. The PCS-C has good reliability and validity for 
children with chronic pain above 9 years [18]. Cronbach’s alpha for our sample was .88 for the 
total score at baseline. 
 
Generalized Anxiety and Depression 
Generalized anxious and depression symptomatology was assessed using the Revised Child 
Anxiety and Depression Scale (RCADS) [11]. The RCADS consists of 47 items which are scored 
on a 4-point Likert scale from never to always. Higher scores indicate increased symptoms of 
anxiety and depression. The RCADS comprises six subscales but here we only calculated scores for 
Generalized Anxiety Disorder (GAD) and Major Depression Disorder (MDD) as we were 
interested in whether ABM training would improve general anxiety and depression 
symptomatology, rather than symptoms related to other anxiety disorders such as separation 
anxiety or social anxiety. The RCADS has yielded good reliability and validity for children and 
adolescents [10,28,42]. Cronbach’s alpha in this study was .86 for the GAD subscale and .86 for 
the MDD subscale at baseline.  
 
Attention Bias Measurement (dot-probe) Task 
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The dot-probe task used to measure attention bias was similar to the placebo training tasks 
(described above), in which participants were presented with stimulus pairs comprising one pain-
related and one neutral stimulus, and were required to identify a probe (a letter ‘p’ or ‘q’). Only 
child picture stimuli (not adult faces or pain words) were used in the attention bias measurement 
task. Like in the placebo training, the pain-related stimuli and probe were presented equally often at 
the top or bottom position of the screen in four possible combinations: pain stimulus top/probe top; 
pain stimulus top/probe bottom; pain stimulus bottom/probe bottom; pain stimulus bottom/probe 
top. Thus, the probe was equally likely to replace either a pain-related stimulus or neutral stimulus. 
Stimuli were presented in a randomized order across trials and participants. Trials were intermixed 
and randomly presented in two blocks, with a break between block one and block two. However, 
unlike the training tasks, each measurement task also began with 20 practice trials comprising 16 
neutral stimulus-pairs, none of which appeared in the experimental trials, as well as four digit trials. 
Thus, in total, each test phase (baseline, post-training, and follow-up) comprised 274 trials (96 
congruent trials, 96 incongruent trials, 64 neutral-neutral trials, 18 digit trials), taking 12 minutes 
for participants to complete. Neutral-neutral trials were included as filler trials to reduce possible 
habituation to pain-related stimuli that might occur if all trials contained pain-related information 
[34]. Participants completed all attention bias measurement tasks at the hospital, using the 
INQUISIT Lab programme on an experimenter-provided computer.  
 
Attention Control Measures 
Participants’ levels of attention control were assessed with one self-report measure and one 
experimental measure.  
The Attention Control Scale (ACS) [23] is a self-report questionnaire that comprises 20 
items, and yields a total score that can range from 20 to 80, with higher scores indicating good 
attention control. The ACS has two subscale scores for attention focusing and attention shifting. 
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The ACS has shown good reliability and predictive utility, predicting resistance to interference in 
Stroop-like spatial conflict tasks as well as attentional disengagement from threat stimuli among 
highly anxious people [23]. Furthermore, Matthews and colleagues [41] showed greater activation 
in brain areas related to top-down regulation of emotion (i.e., rostral anterior cingulate cortex, 
rACC) in those reporting greater attention control. Attention control has also been measured with 
good reliability and validity in children [45]. Cronbach’s alpha in our sample was .81 for the total 
score at baseline.  
The Fish Flanker Task [12,49] is an experimental measure of attention control developed by 
Christ and colleagues [12]. For this task, participants completed a series of computerized trials in 
which they saw a horizontal row of five fish. On each trial, participants were asked to respond as 
quickly as possible as to whether the centre fish was facing to the left or right (using the 
corresponding arrow keys on the computer keyboard). Response times were measured. Two trial 
types were administered: congruent and incongruent. On congruent trials, all five fish in the 
stimulus array pointed in the same direction. On incongruent trials, the four distracting fish pointed 
in the opposite direction of the central target fish. For each trial, stimuli were presented until a 
response was made or until more than 3000ms elapsed. After an inter-trial interval of 1500ms, a 
new trial was presented. If participants failed to respond within 3000ms, a tone and a message 
stating “Too slow” were presented. If participants pressed the incorrect arrow button, a tone and a 
message stating “Wrong response” were presented. Participants completed 120 experimental trials 
(60 congruent and 60 incongruent trials) that were randomly intermixed. Presentation was balanced 
such that all possible stimulus-flanker pairings were equally likely to occur. At intervals of 40 
trials, children were offered a timed 30 second break. Response times on congruent and 
incongruent trials comprised outcome variables for this task.  
 
Subjective Feedback on Training 
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At the post-training assessment, participants completed two six-point visual analogue scales 
(0 = Not at all; 5 = A lot) to gauge their enjoyment in completing the training (‘How much did you 
enjoy doing the training?’) and the degree to which participants thought the training helped them 
(‘How much do you think the training helped you?’).  
 
Materials 
Dot-Probe (Attention Bias) Training and Measurement Stimuli 
Three sets of picture stimuli and one set of word stimuli were used in the ABM training 
tasks. Only picture stimuli were used in the dot-probe assessment tasks, whereas a mixture of 
picture and word stimuli were used for training.  
Stimulus Set One was used at the baseline assessment session and for two of the training 
sessions. Stimulus Set Two was used at the post-training and follow-up assessment sessions, but 
not during the training. Thus, attention biases were examined at the post-training and follow-up 
assessments for non-trained stimuli. For the test phase, both stimulus sets comprised 16 facial 
image stimuli, taken from 8 children (four male and four female). For each stimulus set, 8 picture 
pairs were created. Each pair comprised two pictures of the same child. For each set, in two of the 
pairs the child presented a neutral face in both pictures. These picture pairs were used as filler trials 
(filler trials were not included during the training phase; see [34]). In the remaining 12 picture pairs 
(6 pairs per set), there was one picture with the child presenting a neutral face and one picture with 
the child presenting a pain face. All pain pictures were drawn from video clips of children taking 
part in a cold pressor pain experiment at Ghent University. Stimuli were 160 x 264 pixels in size, 
presented on an Apple Macbook Pro with a 13-inch screen. As these child stimuli were not 
previously validated, we asked participants at the post-training assessment session to rate each 
child face for pain intensity using a 0-10 Numeric Rating Scale (NRS) (i.e., ‘How much pain has 
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the child displayed on the picture; anchors; ‘no pain at all’; ‘a lot of pain’) (see Supplementary 
Materials A for results confirming that stimuli were attributed correctly).  
Stimulus Set Three was used for two of the training sessions. It comprised 12 facial image 
stimuli, presenting six adult faces (three male and three female). Stimuli were 160 x 264 pixels in 
size. All pictures were drawn from one-second video clips of simulated facial expressions of pain. 
These pictures were taken from a larger collection of stimuli, previously created and validated in 
the laboratory by Simon and colleagues [56]. For these stimuli actors were videotaped while 
producing neutral facial displays and simulated facial expressions of different pain intensities. 
Using these 12 pictures, six study slides were generated. Each slide consisted of two pictures of the 
same adult, presenting a neutral face or a moderate pain face. These stimuli have been used in prior 
research examining attention bias to pain (see [60]). The validity of this stimulus set used is 
supported by previous findings of significantly different observer pain ratings between neutral and 
moderate pain facial expressions (see [61]).   
Stimulus Set Four was used for four of the training sessions. The total stimulus set 
comprised 54 pain/neutral word pairs which were matched for length and frequency (see 
Supplementary Materials B for full list of words). However, only 12 word pairs were selected for 
each participant. These pairs were selected in order to best match the quality of pain experienced by 
each individual participant. Therefore, word stimuli were idiosyncratically matched for each 
participant. To select the 12 word pairs for each participant, participants were provided with the list 
of 54 pain-related words at baseline, and were asked to indicate how well each word described 
his/her pain (VAS: 0=Not at all; 5=Perfectly). Based on these ratings, we first selected words with 
the highest ratings (i.e., 5 out of 5). Next, we selected words with successively lower ratings until a 
total of 12 word-pairs were selected. If more than 12 words were possible to select (i.e., with the 
highest ratings), we selected the words with the shortest length. 
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Statistical Analysis Plan 
Incomplete Outcome Data 
Per-Protocol (PP) and Intention-to-Treat (ITT) analyses were conducted. Following 
guidance from the Committee for Proprietary Medicinal Products (CPMP), the ITT analysis is 
considered primary and the PP analysis is considered supportive [31] (PP analysis is presented in 
Supplementary Materials C). Regarding ITT analysis, we used the Baseline Observation Carried 
Forward (BOCF) method. Five participants (7.58% of the full sample) dropped out of the study at 
either the post-training or follow-up assessments, and thus did not provide complete outcome data 
(see Figure 1 for details).  For those participants in attendance at each session, any questionnaires 
in which participants did not complete at least 75% of items are removed for that participant. Mean 
imputation using the relevant subscale for the individual participant’s score is used for 
questionnaire items where less than 25% of the scale is missing.  
 
 
Sample Size Determination 
Given that there are no similar published studies on ABM in youth with chronic pain, nor 
on ABM in adults with chronic pain that compare three groups (i.e., ABM, placebo, and waitlist), a 
minimum sample size of N = 20 in each group was justified a priori on the basis that 1) this exceeds 
the sample size determined by Sharpe and colleagues [53] for their study of ABM in adults with 
chronic pain, for which sample size estimations revealed that n=12 participants per group was 
necessary to achieve 82% power with a significance level of 0.05 (based on findings of an effect 
size of 0.79 from [40]), 2) this exceeds the sample size determined by Eldar and colleagues [27] for 
their study of ABM in youth with anxiety disorders (n = 10-15 in each group), and 3) Simmons and 
colleagues [55] suggest a minimum of N = 20 in each group to reduce the likelihood of false-
positive findings.  
16 
 
Furthermore, earlier ABM studies of adult chronic pain reported large within-group 
comparisons across pain severity indices from pre- to post-intervention, from 0.88 (measure of total 
pain in Schoth et al, 2013) to 1.27 (visual analogue scale of current pain severity in Carleton et al, 
2011). The more recent ABM trial reported by Sharpe and colleagues (2001), which did use a 
control group, reported a between-group effect size of 0.92 on average pain in their first study, and 
a within-group effect size of 0.49 on pain disability in their intervention group in the second study. 
To the extent that these effect sizes are generalizable to our sample and design, n=20 in our 
intervention and control-training group should provide 80% power to detect these effects at p<0.05 
(two-tailed).  
 
Analyses 
All analyses were conducted using SPSS 23.0 software. We first performed a series of one-way 
ANOVAs and chi-square tests to determine whether there were any differences between the three 
randomized groups (ABM, placebo, waitlist) on demographic variables, outcome variables, and 
task measures at baseline. Next, we performed t-tests to determine if participants demonstrated a 
significant attention bias towards pain at baseline, followed by a 2 (Congruency: congruent, 
incongruent) x 3 (Time: baseline, post-treatment, follow-up) x 3 (Group: ABM, placebo, waitlist) 
ANOVA on attention bias and attention control indices to establish whether there was a training 
effect. The main analyses comprised a series of 3 (Time: baseline, post-treatment, follow-up) x 3 
(group: ABM, placebo, waitlist) ANOVAs for outcome variables. If analyses yielded any 
significant interaction effects which, when decomposed, revealed a significant effect of ABM 
training compared to placebo or waitlist, we planned to perform Pearson correlation analyses to 
assess whether change in attention bias or attention control were associated with change in the 
outcome variable. If so, formal mediation analyses were planned.  
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If the sphericity assumption was violated across multiple ANOVA tests (i.e., if Mauchly’s test 
of sphericity was p < 0.05), Greenhouse-Geisser corrections (with adjusted degrees of freedom) 
would be performed and reported for tests. Of note, due to technical difficulties with INQUISIT, 
dot-probe (attention bias) data were unavailable for one participant (in the waitlist group) at 
baseline. Data from this participant were retained in all other analyses. 
 
Dot-Probe Task Data Preparation 
Digit trials were first discarded. Consistent with previous research [7,34,51,61], trials with 
errors, and responses shorter than 200ms or longer than 2000ms were also discarded. Within the 
present sample, the number of errors made by participants ranged from 2-30 (M = 11.06) for the 
baseline assessment, from 1-73 (M = 11.63) for the post-training assessment, and from 1-36 (M = 
9.20) for the follow-up assessment. After discarding these error trials, 0.2% of response times 
(RTs) in the remaining dataset at baseline, 0.4% of RTs in the remaining dataset at post-training, 
and 0.2% of RTs in the remaining dataset at follow-up fell outside the range of 200ms to 2000ms. 
Probe detection latencies that were three SDs above or below the individual mean RT of correct 
responses for each trial type were also considered outliers and thus excluded from analyses 
[7,34,38,61]. This was the case for 1.4% of the RTs in the remaining dataset at baseline, 1.6% of 
the RTs in the remaining dataset at post-training, and 1.7% of the RTs in the remaining dataset at 
follow-up. Filler (neutral/neutral trials) were also discarded before means and SDs were calculated.  
 
Fish Flanker Task Data Preparation 
 Consistent with previous research [12], trials with errors, and responses shorter than 200ms 
or longer than 3000ms, were discarded. Within the present sample, 2% of trials were removed from 
the baseline assessment, 2.3% of trials were removed from the post-training assessment, and 2.3% 
of trials were removed from the follow-up assessment. As with the dot-probe data preparation, RTs 
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that were three SDs above or below the individual mean RT of correct responses for each trial type 
were also considered outliers and thus excluded from analyses. This was the case for 1.7% of the 
RTs on congruent trials and 1.7% of the RTs on incongruent trials in the remaining dataset at 
baseline, 1.8% of the RTs on congruent trials and 1.8% of the RTs on incongruent trials in the 
remaining dataset at the post-training assessment, and 1.9% of the RTs on congruent trials and 
1.6% of RTs on incongruent trials in the remaining dataset at the follow-up assessment.  
 
RESULTS 
Participant Characteristics 
Participant characteristics are presented in Table 1. Time since pain onset varied between 5 
and 170 months (M = 45.7 months, Mdn = 35.5 months). Most participants reported multiple pains, 
with the most common pain problems including joint pain (N = 36, 54.5%), pain in legs or feet (N = 
35, 53%), back pain (N = 33, 50%), and pain in hands or arms (N = 30, 45.5%). Twelve participants 
(18.2%) reported pain all over their body. When asked to indicate the body location where 
participants experienced the most pain, they most often indicated their back (N = 16, 24.2%), legs 
or feet (N = 15, 22.7%), or joints (N = 10, 15.2%). Participants reported moderate levels of 
disability (as indexed by clinical reference points for the FDI; M = 22.79, SD = 10.74, [37]). Forty-
four participants (66.7%) reported experiencing pain every day in the last three months, 20 (30.3%) 
reported pain on most days, and two (3%) reported pain on about one day per week. Thirty-one 
(47%) participants reported that they had taken pain medication at some point in the weeks leading 
up to the study. Randomisation resulted in a balanced distribution across all conditions at baseline, 
with no significant group differences on demographic, outcome, and task assessment measures (see 
Tables 1 & 2). As only one participant dropped out of the study before completing the training, we 
were unable to examine whether there were any significant baseline differences between that 
participant and those participants who completed training. However, visual inspection of mean 
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scores indicates that the participant who dropped out was similar across task and outcome 
measures.  
 
Treatment Adherence 
Out of the 45 participants who commenced either ABM or placebo training, 25 participants 
(55.6%) completed all eight training sessions as scheduled. Of the remaining participants, all 
participants completed five or more training sessions with the exception of one participant who 
dropped out before completing any training sessions (participant excluded from PP analyses).  
 
Intention to Treat Analyses 
Attention Bias Analyses 
Attention Bias at Baseline 
There were no significant differences between RTs to congruent or incongruent trials at 
baseline (t (64) = 0.33, p = .74), and the calculated attention bias score was not significantly 
different from zero at baseline (t (64) = -0.33, p = .74), indicating no attentional biases to pain-
related stimuli across the whole sample (see Table 2 for means and SDs). 
Change in Attention Bias Following Training 
A 2 (Congruency: congruent, incongruent) x 3 (Time: baseline, post-treatment, follow-up) x 
3 (Group: ABM, placebo, waitlist) ANOVA was conducted for dot-probe scores to assess whether 
a reliable training effect of ABM could be determined (see Table 2 for means and SDs; see Table 3 
for ANOVA results). Analyses revealed a significant main effect for time, indicating that all 
participants, regardless of training, had faster RTs with proceeding time. Bonferroni-corrected 
analyses of simple main effects revealed that RTs were significantly faster at each assessment 
session (baseline to post-training: p < .001; post-training to follow-up: p = .01; baseline to follow-
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up: p < .001). There were no other significant main effects, and no significant interactions effects. 
Thus, the predicted training effect was not observed. 
 
Primary Outcome Measures 
A series of 3 (Time: baseline, post-treatment, follow-up) x 3 (Group: ABM, placebo, 
waitlist) ANOVAs were conducted on pain symptoms (see Table 2 for means and SDs; see Table 3 
for ANOVA results). There was a significant main effect of time for pain duration, indicating that 
all participants, regardless of training, experienced pain for less time each day with proceeding 
time. Bonferroni-corrected analyses of simple main effects revealed that participants experienced 
significantly less pain at follow-up compared to baseline (p = .01) but not compared to post-
training (SPSS adjusted p = 1.0), nor at post-training compared to baseline (p = .09). There were no 
significant main effects for average pain or most problematic pain, and contrary to our hypotheses, 
there were no significant interaction effects. Due to the absence of significant group differences on 
primary measures, effect sizes (with 95% confidence intervals) were thought to be important for 
planning future studies, specifically regarding sample size considerations. We therefore calculated 
effect sizes of differences between the ABM and placebo group at post-intervention for: pain at 
most problematic site, -0.127 (95% CI: -0.712 to 0.458); average pain, -0.536 (95% CI: -1.131 to 
0.05); and pain duration, 0.221 (95% CI: -0.365 to 0.807).  
 
Secondary Outcome Measures  
A series of 3 (Time: baseline, post-training, follow-up) x 3 (Group: ABM, placebo, waitlist) 
ANOVAs were conducted on secondary outcome measures (see Table 2 for means and SDs; see 
Table 3 for ANOVA results). There were main effects of time for functional disability (baseline to 
post-training: p < .001; baseline to follow-up: p < .001; post-training to follow-up: p = .04), pain 
catastrophizing (baseline to post-training: p < .001; baseline to follow-up: p < .001; post-training 
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to follow-up: p = .12), generalized anxiety (baseline to post-training: p = .04; baseline to follow-
up: p = .01; post-training to follow-up: p = .40), depression symptoms (baseline to post-training: p 
= .37; baseline to follow-up: p = .04; post-training to follow-up: p = .21), sit-to-stand task 
(baseline to post-training: p = .03; baseline to follow-up: p = .002; post-training to follow-up: p = 
.12), and cardio wall task (baseline to post-training: p < .001; baseline to follow-up: p < .001; 
post-training to follow-up: p = 1.0), indicating that participants reported improved scores over time 
on these measures, regardless of training group. There were no other significant main effects, and 
there were no significant interaction effects. As for primary outcomes, effect sizes (with 95% 
confidence intervals) of differences between the ABM and placebo group at post-intervention were 
calculated for: functional disability, 0.032 (95% CI: -0.552 to 0.617); pain catastrophizing, -0.147 
(95% CI: -0.733 to 0.438), generalized anxiety, -0.084 (95% CI: -0.669 to 0.501), depression 
symptoms, 0.084 (95% CI: -0.501 to 0.669), attention control, -0.230 (95% CI: -0.817 to 0.356), 
sit-to-stand task, 0.366 (95% CI: -0.224 to 0.955), and cardio wall task, 0.213 (95% CI: -0.373 to 
0.800).  
 
Attention Control Analyses 
Change in Attention Control after Training 
To examine whether ABM training changed self-reported attention control, we conducted a 
3 (Time: baseline, post-training, follow-up) x 3 (Group: ABM, placebo, waitlist) ANOVA with the 
Attention Control Scale (ACS) score as the outcome variable (see Table 2 for means and SDs; see 
Table 3 for ANOVA results). There was a significant main effect of time, indicating that that all 
participants, regardless of training, reported higher attention control over time. Bonferroni-
corrected analyses of simple main effects revealed that participants reported significantly higher 
attention control at follow-up than at baseline (p = .02). Self-reported attention control did not 
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significantly differ between baseline and post-training (p = .15) or between post-training and 
follow-up (p = .49). There were no significant interaction effects. 
To examine whether ABM training changed experimentally-measured attention control, we 
conducted a 2 (Congruency: congruent, incongruent) x 3 (Time: baseline, post-treatment, follow-
up) x 3 (Group: ABM, placebo, waitlist) ANOVA for RTs on the flanker task (see Table 2 for 
means and SDs; see Table 3 for ANOVA results). There was a significant main effect of 
congruency, indicating that participants were slower on incongruent than congruent trials (p < 
.001). There was also a significant main effect of time, indicating that participants, regardless of 
training, had faster RTs with proceeding time. Bonferroni-corrected analyses of simple main effects 
revealed that participants were significantly faster at follow-up compared to baseline (p = .01) and 
at follow-up compared to post-training (p = .01). Participant RTs did not significantly differ 
between baseline and post-training (p = 1.0). There were no other significant main effects, and no 
significant interactions effects.  
 
Adverse Events 
No adverse events reported by participants were study-related. No participants reported 
adverse events immediately following the baseline session. Eight participants reported adverse life 
events at the post-training assessment, and eight participants reported adverse life events at the 
follow-up assessment. These were flu (N = 1), illness or death of a non-immediate family member 
(N = 3), visits to hospital emergency departments (N = 1), accident-related injury (N = 1), parent in 
accident (N = 1), minor medical procedures (N = 1), difficulties at school (N = 3), and death of a 
pet (N = 1). Eight of these participants also reported pain or other physical symptoms as a specific 
adverse event; however, these were reported as unrelated to the study procedures. There were no 
significant differences in the number of adverse events reported between groups.  
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Subjective Feedback 
Participants who completed ABM or placebo training reported that they moderately enjoyed 
completing the training (M = 3.58, Range = 2-5), and that they believed the training moderately 
helped them (M = 2.66, Range = 0-5). When asked to predict whether they received ABM or 
placebo training, 29 participants (65.9%) thought that they had completed placebo training, and 
there was no significant difference between groups in predicted training received (ABM group: 16 
(72.7% placebo); placebo group (13 (59.1% placebo); X² (1) = 0.91, p = .34).  
 
DISUCSSION 
This study presents a randomized placebo-controlled trial of multi-session Attention Bias 
Modification (ABM) for adolescents with chronic pain. We are not able to reject the null 
hypothesis that the treatment, placebo training, and wait-list control groups differed. There were no 
significant differences between ABM training and placebo training or no training (waitlist) groups 
on pain symptoms. There were also no significant differences between ABM training, placebo 
training, or wait-list control groups on pain catastrophizing, generalized anxiety and depression 
symptoms, and physical functioning immediately after training or at 3-month follow-up. ABM 
training did not significantly impact attention bias or attention control in comparison to placebo 
training and no training; thus, the hypothesized training effect was not observed. Effect sizes for 
group comparisons between the ABM and placebo training condition from baseline to post-training 
were mostly small. There was a moderate effect size for the comparison of average pain level, 
however this (non-significant) effect was in the opposite direction than expected, with the ABM 
group actually reporting increased pain at post-training and the placebo group reporting reduced 
pain. Findings were similar across per-protocol and intention-to-treat analyses.  
Our findings are somewhat inconsistent with previous findings demonstrating improved pain-
related outcomes from ABM. Most relevant for comparison are two placebo-controlled studies that 
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have investigated ABM in adults with chronic pain [9,53]. First, Carleton and colleagues [9] found 
that adult fibromyalgia patients reported reduced pain scores following ABM training. Second, 
Sharpe and colleagues [53] found that adult chronic pain patients reported improvements in 
functional disability following ABM training. In addition, both studies found improvements in a 
small number of pain-related cognitive-affective factors, including anxiety sensitivity [9,53] and 
pain-related fear [9]. We did not replicate these findings with our sample of adolescents with 
chronic pain. A number of differences between the current and previous studies may explain 
inconsistencies. First, we did not measure anxiety sensitivity or pain-related fear; it may be that 
ABM influences only these specific constructs, or that training effects are stronger in subgroups of 
patients with high anxiety sensitivity or fear of pain. Thus these traits measured at baseline could 
moderate training effects. Second, we used a wider variety of training materials. Third, we 
administered fewer training trials per session, and fewer sessions overall than some prior adult 
ABM studies. ABM trials conducted in children and adolescents on mental health indices offer 
little consensus on the optimal number of sessions to enhance effectiveness [16]. Therefore, with 
the goal to maintain engagement among youth (and avoid boredom and fatigue), we decided in 
consultation with experienced clinicians to limit training to no more than 15 minutes, resulting in 
around 192 trials per session. Finally, participants in the current study completed all training 
sessions at home, whilst in previous studies training was completed partially or entirely in the 
clinic. It has been argued that at-home ABM training may be negatively influenced by the 
participant being in comfortable and familiar surroundings, whereas a level of mild anxiety, for 
example by visiting the clinic, is necessary for activating (and therefore changing) threat-related 
biases [8]. Completing the task at home may also have meant relatively less engagement with 
training by the participants due to the absence of an experimenter and/or the presence of 
uncontrolled distractions (although of note, we obtained high accuracy/fast response times).  
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Some of our findings are consistent with other studies of ABM for chronic pain and 
psychopathology populations. First, there was no evidence of a pain-related attention bias at 
baseline in our sample, and no evidence that biases changed following training, thus replicating 
findings from Sharpe and colleagues [53]. This may explain our null findings. The absence of an 
attention bias at baseline could be due to a number of factors. A recent meta-analysis of attention 
biases in child and adolescent anxiety suggested that use of pictorial over linguistic stimuli and the 
presentation of ‘threat’ stimuli for longer durations (1000ms rather than 500ms) were variables that 
moderated the link between attention bias and anxiety [24]. Moreover, anxiety-associated attention 
biases were more likely to characterize older than younger youth, and other studies have also 
suggested complex interactions between attention control, attention bias and anxiety [21]. These 
methodological and sample considerations should be taken into account in future ABM trials to 
ensure a) the optimal assessment of biases, and b) that the sample selected manifest biases that 
could be shifted through training. Speaking to this, studies of ABM efficacy for anxiety and 
depression disorders indicate that effects on outcomes are most consistently found when biases 
exist at baseline [30] and when training successfully changes biases [13]. On the other hand, Sharpe 
and colleagues [53] demonstrated effects of ABM training on pain-related outcomes despite no 
change in attention bias. These discrepancies may be because of methodological issues, notably 
that the dot-probe task does not demonstrate good reliability as a measurement tool in pain 
populations [22], especially in children and adolescents where greater noise and variability may be 
present [20]. Changes in biases following ABM training, or a lack thereof, may therefore not be a 
reliable indicator of actual changes in attentional functioning. Our findings are also consistent with 
more recent ABM studies in anxiety and depression. Although meta-analyses of CBM in adults 
with anxiety have consistently found at least small but significant effects [17], the only child-
specific meta-analysis has failed to find evidence of benefit in children and young people [16]. 
Where significant findings have been reported in individual trials, effect sizes are generally low, as 
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demonstrated here as well. Given this, our trial is likely underpowered for the detection of these 
weak effects.  
Nonetheless, our study design had significant advantages compared to previous studies on 
ABM in pain populations. First, word stimuli were idiosyncratically selected to match the quality 
of each participant’s pain. Personal relevance of pain stimuli may be important for eliciting biases 
[21]. Therefore ABM training may be most efficacious when using such personalized stimuli. 
Second, we included two physical tasks (the sit-to-stand task and the cardio wall task) that provided 
objective measures of physical functioning. These tasks are frequently used in physiotherapy 
sessions and reflect measures that are used in clinical practice to make decisions about patients’ 
treatment needs and progress. Third, given recent suggestion that ABM may impact attention 
control rather than valence-specific attentional selectivity [6], we considered the impact of ABM 
training on attention control, including both a self-report and an experimental measure. Although 
ABM training did not change attention control in our data,, future studies may consider including 
other measures of attention control, for example, the Attention Network Test (that is designed to 
test alerting, orienting, and executive control) [29], as well as antisaccade tasks (that are reliant on 
inhibitory eye-movement patterns) [36]. These other tasks could be designed to tap control of 
attention in pain-specific contexts rather than general trait abilities, as measured here, using the 
Attention Control Scale.  
Findings presented here also add to our understanding of intervention delivery in pediatric 
chronic pain populations. First, recruitment of patients into the study was very successful: most 
patients approached by the team agreed to take part. Anecdotal evidence from the current study 
suggests that the computer-game interface was appealing to participants, suggesting that future 
interventions using a similar interface may achieve a similarly high recruitment success rate.  
Second, retention was high and while we collected data remotely, training indices revealed high 
levels of accuracy and fast response times. Subjective feedback also indicated moderate levels of 
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task enjoyment and perceived usefulness of the training. This information is particularly important 
given current concerns over the face validity of computerized ABM training in adult samples [1]. 
Given the need for novel interventions that are both cost-effective and easy-to-access, we provide 
evidence that computerized training may be a promising platform for delivering interventions to 
youth with chronic pain. Of note, we also found improvements across all groups on a number of the 
task and questionnaire measures over time. These improvements could be explained in part by 
positive engagement with clinical services during assessments and by practice effects for the 
cognitive and physical tasks.  
In conclusion, we report here the first randomized-controlled trial of ABM in a clinical sample 
of adolescents with chronic pain. We found no evidence that ABM affected pain symptoms 
compared with placebo training or wait-list control, or other pain-related outcomes. ABM also did 
not change attention bias or attention control in comparison with placebo training or no training, 
thus we did not find the predicted training effect. Calculated effect sizes on primary outcomes at 
post-intervention were also small. However, before we disregard ABM as a potential intervention, 
there are also a number of methodological reasons, and sample considerations that could have 
explained these null findings. Tailoring possible ABM to patients most likely to benefit from direct 
attentional re-direction (including recruitment of patients with more homogenous pain complaints) 
is a priority for future ABM trials. It may be that selecting those with extreme attentional biases, 
fear of pain, anxiety sensitivity and poor attention control would enable training effects to be 
observed more clearly. Other tools may also be needed to better shift attention biases. For example, 
given recent theory suggesting that attention biases are driven by biased interpretations of pain and 
pain-related information [19,58], and recent evidence that pain-related interpretation biases 
characterize adolescents with chronic pain [32], training tools that target interpretation biases (or 
other theoretical antecedents of attention bias) may also be useful for investigating the role of 
cognitive biases in pediatric chronic pain going forward [50]. 
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FIGURE LEGENDS 
Figure 1. CONSORT diagram illustrating the flow of participants through the study. 
Figure 2. Example trial from the one of the ABM training tasks.  The stimuli used during ABM 
were either faces (shown) or words. On each trial a fixation cross was presented, followed by two 
stimuli (pain/neutral or neutral/neutral), followed by a probe (p or q) to which the patients had to 
respond. During ABM (shown) the probe appeared behind the neutral stimulus; the placebo ABM 
condition was identical in every respect other than that the probe was equally likely to appear 
behind either the neutral or pain stimulus. Nb., stimuli are not presented to scale.  
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Table 1. Baseline demographic and pain characteristics 
Measure ABM (n=23) Placebo (n=22) Waitlist (n=21) Total (n=66) 
Demographics     
Sex [female] 20 (87.0%) 17 (77.3%) 18 (85.7%) 55 (83.3%) 
Age [years] 13.48 (2.15) 13.95 (2.04) 14.52 (2.18) 13.97 (2.13) 
Ethnicity      
    Caucasian 21 (91.3%) 21 (95.5%) 19 (90.5%) 61 (92.4%) 
    Asian 1 (4.3%) 1 (4.5%) 1 (4.8%) 3 (4.5%) 
    Other 1 (4.3%) 0 (0.0%) 1 (4.8%) 2 (3.0%) 
Has siblings 21 (91.3%) 20 (90.9%) 18 (85.7%) 59 (89.4%) 
     
Pain variables     
Time since pain onset [months] 44.70 (34.58) 39.18 (23.66) 53.48 (45.25) 45.65 (35.35) 
Attends full time school 19 (82.6%) 18 (81.8%) 14 (66.7%) 51 (77.3%) 
Pain onset (gradual) 13 (56.5%) 10 (45.5%) 16 (76.2%) 39 (59.1%) 
Pain in more than one area  21 (91.3%) 20 (90.9%) 17 (81.0%) 58 (87.9) 
Pain at most problematic site [/10, last week] 7.48 (1.83) 6.86 (1.64) 7.52 (1.63) 7.29 (1.71) 
Average pain [/10, last week] 6.09 (1.86) 6.18 (1.89) 6.33 (2.06) 6.20 (1.91) 
Pain duration [/4, last week] 3.17 (0.94) 3.39 (0.87) 3.67 (0.66) 3.39 (0.87) 
Categorical variables: N (%); Ordinal/continuous variables: Mean (SD) 
Nb. No significant differences between groups on any measures 
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Table 3. ANOVA results for all outcome measures (ITT analysis).  
Measure Effect df F p 2
ph  
Primary outcomes      
Pain at most problematic site Time 1.93,121.73 2.66 .08 .04 
 Group 2,63 0.89 .42 .03 
 Time x Group 3.86,121.73 0.43 .78 .01 
Average pain (last week) Time 1.70,106.78 2.30 .11 .04 
 Group 2,63 0.45 .64 .01 
 Time x Group 3.39,106.78 1.82 .14 .06 
Pain duration (last week) Time 1.88,118.54 4.58 .01 .07 
 Group 2,63 2.96 .06 .09 
 Time x Group 3.76,118.54 0.61 .65 .02 
Secondary outcomes      
FDI Time 1.83,115.20 19.79 .00 .24 
 Group 2,63 0.20 .82 .01 
 Time x Group 3.66,115.20 0.56 .67 .02 
PCS-C Time 1.70,107.13 16.85 .00 .21 
 Group 2,63 1.38 .26 .04 
 Time x Group 3.40,107.13 0.97 .42 .03 
RCADS-Depression Time 1.71,107.58 4.74 .02 .07 
 Group 2,63 0.61 .55 .02 
 Time x Group 3.42,107.58 1.99 .11 .06 
RCADS-Generalised anxiety Time 1.64,103.13 6.20 .01 .09 
 Group 2,63 1.15 .32 .04 
 Time x Group 3.27,103.13 2.09 .10 .06 
Sit-to-stand task Time 1.69,106.36 8.75 .00 .12 
 Group 2,63 1.50 .23 .05 
 Time x Group 3.38,106.36 1.30 .28 .04 
Cardio wall task Time 1.90,119.45 15.08 .00 .19 
 Group 2,63 0.63 .53 .02 
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Figure 2 
